scispace - formally typeset
Open AccessJournal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
- Vol. 397, Iss: 10277, pp 881-891
TLDR
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
About
This article is published in The Lancet.The article was published on 2021-03-06 and is currently open access. It has received 862 citations till now. The article focuses on the topics: Booster dose & Vaccine efficacy.

read more

Citations
More filters
Journal ArticleDOI

Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond.

TL;DR: In this paper, the authors provide an overview of SARS-CoV-2 vaccine development for older adults, highlighting clinical data on the influenza, Streptococcus pneumoniae and herpes zoster vaccines, and summarizes recent developments to improve vaccine efficacy, such as the use of adjuvants or higher antigen dose for influenza.
Journal ArticleDOI

Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study

TL;DR: In this paper , a phase 2b part of a randomized phase 2/3 study assessed the efficacy and safety of ensitrelvir for mild-to-moderate coronavirus disease 2019 (COVID-19) during the Omicron epidemic.
Journal ArticleDOI

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern

TL;DR: Current SARS-CoV-2 variants, the protective efficacy of vaccines against VOCs, and the shortcomings in methods for evaluating vaccine efficacy are summarized and strategies for responding to variants are proposed.
Journal ArticleDOI

COVID-19 vaccine reactogenicity – A cohort event monitoring study in the Netherlands using patient reported outcomes

TL;DR: In this article , the authors explore factors that are associated with reactogenicity in general and systemic after the first dose of COVID-19 vaccine in the Netherlands, and they show that, taken into account all factors in the model, the Comirnaty® vaccine gave the least and the Vaxzevria® vaccine the most reactionogenicity.
Journal ArticleDOI

Efficiency in COVID-19 Vaccination Campaigns-A Comparison across Germany's Federal States.

TL;DR: In this article, the authors evaluate the efficiency of a country's vaccination campaign and find that the integration of doctors' offices into a campaign that formerly relied only on vaccination centers significantly increased the ratio of vaccinations administered out of a given stock of vaccine doses.
References
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -